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Abstract
Introduction Reactivation of hepatitis B virus (HBV) infection in
patients with past infection has been described in 5% to 10%
of individuals undergoing immunosuppressive therapies. No
data are available to date on the outcome of patients treated by
tumour necrosis factor-alpha (TNFα) inhibitors for chronic
arthritis with a serological pattern of past HBV infection. The aim
of our study was to monitor HBV markers in HBV surface
antigen (HBsAg)-negative/anti-HBcAb-positive patients treated
with a TNFα inhibitor for inflammatory arthritides.
Methods Twenty-one HBsAg-negative/anti-HBcAb-positive
patients were included. HBV serological patterns were
compared with those determined before starting TNFα
inhibitors. Serum HBV DNA testing by polymerase chain
reaction was additionally performed. Spearman correlation
analysis was used and P < 0.05 was chosen as the significance
threshold.
Results Before starting therapy, mean anti-HBsAb titre was 725
IU/L, no patient had an anti-HBsAb titre <10 IU/L, and 18
patients had an anti-HBsAb >100 IU/L. At a mean time of 27.2
months following therapy introduction, mean anti-HBsAb titre
was 675 IU/L and anti-HBsAb titre remained >100 IU/L in 17
patients. There was a strong correlation between the first and
second anti-HBsAb titres (r = 0.98, P = 0.013). Moreover, no
patient had an anti-HBsAb titre below 10 IU/L or HBV
reactivation (HBsAg seroreversion or positive HBV DNA
detection). However, the anti-HBsAb titre decreased by more
than 30% in 6 patients. The mean anti-HBsAb titre at baseline
was significantly lower (P = 0.006) and the mean duration of
anti-TNFα therapy, although non-significant (P  = 0.09), was
longer in these six patients as compared to patients without a
decrease in anti-HBsAb titre.
Conclusions Anti-TNFα treatments are likely to be safe in
patients with past hepatitis B serological pattern. However, the
significant decrease of anti-HBsAb titre observed in a
proportion of patients deserves HBV virological follow-up in
these patients, especially in those with a low anti-HBsAb titre at
baseline.
Introduction
Hepatitis B virus (HBV) reactivation is a life-threatening dis-
ease that is known to occur in HBV inactive carriers following
polychemotherapy or immunosuppressive treatments. Thus,
HBV reactivation has been reported to occur in up to 50% of
HBV surface antigen (HBsAg)-positive patients following poly-
chemotherapy for haematological cancer [1], and in these
patients, preventive anti-HBV therapy is recommended [2]. In
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addition, several studies have pointed out that HBV reactiva-
tion was possible, though at a much lower frequency, in
patients undergoing immunosuppressive chemotherapy and
whose HBV serological patterns indicate past hepatitis B, as
defined by HBsAg negativity and anti-HBV core antibody pos-
itivity resulting in severe acute hepatitis and significant morbid-
ity and mortality rates despite antiviral therapy.
Tumour necrosis factor-alpha (TNFα) inhibitors that are widely
used in chronic inflammatory arthritides, inflammatory bowel
diseases, and psoriasis treatment are likely to interfere with the
natural history of chronic HBV infection. Production of TNFα
has been shown to be elevated in the liver of patients chroni-
cally infected with HBV; TNFα participates in the clearance of
HBV by promoting elimination of HBV-infected hepatocytes
and inhibiting HBV replication. More recently, TNFα has been
shown to play a key role in the control of the immune response
directed against HBV. Thus, TNFα may inhibit the suppressive
effect of regulatory T cells on the HBV-specific immune
response and lack of TNFα induces impaired proliferation of
HBV-specific cytotoxic T lymphocytes [3]. TNFα inhibitors are
therefore likely to promote HBV replication and reactivation. In
this view, some case reports have had a fatal outcome
because of HBV reactivation following infliximab administra-
tion in HBsAg-positive patients [4-9]. In these patients, TNFα
inhibitors should not be used without preventive anti-HBV
therapy. Except for one case report [10], no data are available
to date in the outcome of patients treated with TNFα inhibitors
for chronic inflammatory arthritides with a serological pattern
of past HBV infection, although this serological status is much
more frequently encountered as compared with HBsAg posi-
tivity. In the present work, we aimed at detecting HBV reacti-
vation in a cohort of patients with past HBV infection who
underwent TNFα inhibitor treatment for chronic inflammatory
rheumatism.
Materials and methods
Patients
Selection of anti-TNFα-treated patients and hepatitis B virus 
serological patterns
Five hundred four patients followed in the department of rheu-
matology were tested for hepatitis B serological pattern
between 2005 and 2006. Of them, 284 had a totally negative
serology, 2 (0.4%) had a serology indicating chronic hepatitis
B (HBsAg positivity), and 58 (13%) had an HBV serology indi-
cating spontaneously cured hepatitis B (HBsAg-negative, anti-
HBcAb-positive, ± anti-HBeAb-positive); 54 of these 58
patients were anti-HBsAb-positive and the remaining 4 were
anti-HBsAb-negative. In addition, 8 patients harboured iso-
lated anti-HBcAb (without anti-HBsAb or anti-HBeAb). Finally,
152 patients had a serological pattern in agreement with HBV
vaccination (isolated anti-HBsAb positivity). Twenty-four of the
58 patients with a serology indicating cured hepatitis B were
treated for rheumatoid arthritis (RA) or spondylarthropathy by
one or more anti-TNFα. Three of them could not be included
in this study: one died, one withdrew consent, and one was
lost to follow-up. Finally, a total of 21 patients gave informed
consent for the study and were included.
Methods
Peripheral blood analyses, including blood count, transami-
nase activity (aspartate transaminase [AST] and alanine
transaminase [ALT]), gamma-glutamyl transferase [GGT],
bilirubin dosage, and hepatitis B serological pattern before
anti-TNFα treatment and during follow-up, were compared.
The mean duration between the two blood samples was 35
months (range 12 to 60 months). Additionally, HBV DNA
detection using polymerase chain reaction (PCR) was per-
formed in the last serological pattern determination.
Detection of hepatitis B viral DNA
Quantification of viral DNA was performed using a real-time
PCR assay (Cobas Ampliprep/Cobas TaqMan 48 assay;
Roche Diagnostics, Meylan, France). The detection threshold
was 12 IU/L (1.08 log IU/mL, or 70 copies/mL).
Anti-HBs antibody dosage
Anti-HBsAb quantification was performed using the Axsym
Abbott immunoenzymatic assay (Abbott Diagnostics, Wies-
baden, Germany). An anti-HBsAb titre of less than 10 IU/L
was considered negative. An anti-HBsAb titre of greater than
100 IU/L was considered to represent good protective
immune status in a healthy subject, even if it is admitted that a
greater than 10 IU/L titre is sufficient for conferring a protec-
tive effect against HBV after immunization [11]. HBsAg and
anti-HBcAb were detected using Axsym Abbott immunoenzy-
matic assays.
Statistical analysis
The difference of anti-HBsAb titre between the first and sec-
ond serum samples was analysed using a non-parametric test:
the Spearman rank correlation coefficient. A P value of less
than 0.05 was chosen as the significance threshold. AST,
ALT, and GGT levels and bilirubin dosage were considered to
increase when there was twofold elevation.
Results
Baseline characteristics of the 21 patients included
The baseline characteristics of the 21 patients before the first
blood test analysis are as follows: the majority of patients
(62%) were women, patients had a mean age ± standard devi-
ation of 57.7 ± 2.7 years (range 38 to 81), and the disease
duration was 11 ± 2.2 years (range 1 to 30). Twelve patients
suffered from RA, 5 from psoriasic arthritis, and 4 from anky-
losing spondylarthritis (AS). At the end of the study, 4 patients
were treated with infliximab, 14 with etanercept, and 3 with
adalimumab. Thirteen patients received only one TNFα inhibi-
tor: 8 were treated with etanercept, 3 with adalimumab, and 2
with infliximab. Because of non-response to one TNFα inhibi-
tor, 6 patients had two types of TNFα inhibitors, and 2 patientsAvailable online http://arthritis-research.com/content/11/6/R179
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did not respond to two TNFα inhibitors but benefited from
three TNFα inhibitors. TNFα inhibitor dosage was usual: 50
mg per week for etanercept, 40 mg twice a month for adalimu-
mab, and 3 to 5 mg/kg for 8 weeks (RA patients) or 6 weeks
(AS patients) for infliximab. Ten of the 21 patients also
received methotrexate (7.5 to 15 mg per week). The mean
duration of treatment was 27.2 months (range 7 to 56).
Hepatitis B serology, hepatitis B viral detection, and liver 
enzymes
Initial anti-HBsAb titre analysis
Three patients (one with RA and two with AS) had an anti-
HBsAb titre of less than 100 IU/L at the first blood analysis:
16, 22, and 94 IU/L.
Anti-HBsAb titre evolution
The anti-HBsAb titre remained greater than 10 IU/L in all
patients at the second blood analysis (the lowest titre was 12
IU/L). A tendency for the decrease of anti-HBsAb titre by an
average of 48 IU/L (8%) in comparison with the first measure-
ment was observed. No patient had an increase in anti-HBsAb
titre. Before the start of therapy, the mean anti-HBsAb titre
was 725 IU/L, and at the second sample, the mean anti-
HBsAb titre was 675 IU/L. There was a strong correlation
between the anti-HBsAb titre of the first and second blood
samples (r = 0.98, P = 0.013) (Figure 1a, b). Only 1 of 21
patients experienced a decrease of anti-HBsAb level below
100 IU/L, from 256 to 80 IU/L. A subgroup of six patients
experienced a significant decrease in anti-HBsAb titres, rang-
ing from 30% to 70%. In these six patients, the mean anti-
HBsAb titre at baseline was significantly lower (P = 0.006),
and although it did not reach significance, the mean duration
of anti-TNF therapy was longer (P = 0.09) as compared with
patients who did not present a decrease in anti-HBsAb. Four
of them had a therapeutic association with methotrexate
(Table 1).
Hepatitis B virus reactivation
No hepatitis B reactivation, as defined by HBsAg or HBV DNA
detection, was observed.
Liver enzyme evolution
At the beginning of the study, three patients had significant
abnormalities of liver enzymes, even if only one of them had a
methotrexate association. At the time of the second blood
sample, only one patient (not one of the three previous
patients) had significant abnormalities; she was treated with
methotrexate. All patients had a normal platelet count.
Discussion
The main result of the present work is that we did not observe
HBV reactivation following TNFα inhibitor treatment in
patients with a serological pattern of past HBV infection. This
is a very important result. Indeed, although TNFα inhibitors are
likely to interfere with the natural history of chronic HBV infec-
tion and HBV reactivation has been described in HBsAg-pos-
itive patients following TNFα inhibitors (including case reports
with a severe or fatal outcome), no clear recommendation for
the management of patients presenting a serological status of
past HBV infection exists to date.
HBV reactivation in patients with serological tests of past HBV
infection (that is, HBsAg-negative, anti-HBcAb-positive with or
without anti-HBsAb) has been previously described following
immunosuppressive therapies or polychemotherapy, espe-
cially those including biotherapies such as rituximab [12]. In
these cases, HBV reactivation is explained by the persistence
of HBV DNA inside the hepatocyte nucleus [13]. This allows
the reappearance of HBV replication in a context of immune
suppression [14]. The risk of HBV reactivation following TNFα
inhibitors in such patients is therefore a concern and was
recently underlined [4].
Figure 1
Correlation between group 1 and 2 anti-HBs Ab titre Correlation between group 1 and 2 anti-HBs Ab titre. (a) Correlation 
between anti-HBsAb titre of the first (baseline) and second (end of fol-
low-up) dosages (anti-HBsAb 1 and anti-HBsAb 2, respectively). The 
coefficient of correlation is r = 0.98, and P = 0.013 by the Spearman 
rank correlation. (b) Evolution of anti-HBsAb titre for each patient 
between the first (1) and second (2) dosages.Arthritis Research & Therapy    Vol 11 No 6    Charpin et al.
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Moreover, this serological profile is frequently encountered.
The rates of prevalence of this serological profile in the general
population in France in 2004 were estimated to be 9.7% for
men and 6.7% for women [15]. Thus, in the present study,
13% of the 504 patients from the department of rheumatology
presented with an HBV serology indicating spontaneously
cured hepatitis B.
The present work is the first to assess the safety of TNFα
inhibitors in a cohort of patients with a serological pattern of
past HBV infection, and although a larger number of patients
should be necessary to draw a firm conclusion, it strongly sug-
gests that the risk of TNFα inhibitor-related HBV reactivation
is very low in these patients, even after several years of ther-
apy. A longer follow-up of these patients, however, should be
mandatory. Hence, although anti-HBsAb titre always remained
higher than 10 IU/L and a very strong correlation between the
first and second anti-HBsAb titres could be observed for each
patient (r = 0.98, P = 0.013), a large decrease (30% to 70%)
of anti-HBsAb titres could be noted in a significant proportion
(6 of 21 patients) of TNFα inhibitor-treated patients, especially
those presenting with a low anti-HBsAb at baseline. This point
should be taken into consideration because such a decrease
in anti-HBsAb titre has been shown to precede HBV reactiva-
tion in patients treated for haematological cancer or following
immunosuppressive therapy [16], stressing the need for a
closer follow-up of these patients. Although the difference did
not reach significance, it is noteworthy that the mean duration
of anti-TNFα therapy was longer in these six patients than in
those in whom anti-HBsAb titre remained stable. A more pro-
longed follow-up of these patients will therefore be necessary.
This decrease in anti-HBsAb titre might also be related to the
underlying chronic disease itself as well as other coincidental
factors such as concurrent immunosuppressive therapy. In this
view, it is worth noting that four of six patients with a large
decrease in anti-HBsAb titres were also treated with meth-
otrexate. Further studies will also be necessary to assess the
risk of HBV reactivation in patients undergoing biotherapies
other than anti-TNFα treatment.
Conclusions
Although further studies that include more patients with a
longer follow-up are necessary, it is likely that anti-TNFα treat-
ments can be safely used in patients treated for chronic inflam-
matory arthritides with an HBV serological pattern indicating
past hepatitis B. Thus, no HBV reactivation was observed after
a mean of 27 months of anti-TNFα treatment. In addition, anti-
HBsAb titre remained above 10 IU/L for all patients. However,
the decrease of anti-HBsAb titre observed in a significant pro-
portion of patients suggests that HBV virological follow-up
should be considered during anti-TNFα therapy in patients
with past HBV infection.
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